Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kristina James

Nurse Practitioner, Family Gainesville, GA Nurse Practitioner

NPI 1912452061 CMS profile 11003058

1240 Jesse Jewell Pkwy Se, Suite 400, Gainesville, GA 30501

Open in the dashboard

General payments

$16,269

724 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kristina James of Gainesville, GA is reported in the CMS Open Payments database as having received $16,269 across 724 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,095 131
2024 General $3,771 150
2023 General $3,382 150
2022 General $2,709 134
2021 General $3,312 159

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kristina James
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Kristina James were reported at $3,095. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Kristina James Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $3,312 $124 $35–$379 $132
2022 $2,709 $141 $44–$430 $149
2023 $3,382 $154 $49–$476 $160
2024 $3,771 $165 $51–$504 $164
2025 $3,095 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,191 108 payments
  2. UCB, Inc. $1,175 49 payments
  3. Pfizer Inc. $1,079 59 payments
  4. Neurelis, Inc. $748 26 payments
  5. US WorldMeds, LLC $638 21 payments
  6. Neurocrine Biosciences, Inc. $590 22 payments
  7. Novartis Pharmaceuticals Corporation $587 35 payments
  8. Biogen, Inc. $572 23 payments
  9. Lundbeck LLC $550 20 payments
  10. Amgen Inc. $486 21 payments
  11. Other $7,654 340 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $16,269 724 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $902 55 payments
  2. QULIPTA $837 50 payments
  3. VALTOCO $748 26 payments
  4. NURTEC ODT $721 42 payments
  5. Briviact $641 33 payments
  6. INGREZZA $590 22 payments
  7. APTIOM $488 20 payments
  8. AIMOVIG $486 21 payments
  9. VYEPTI $454 16 payments
  10. NOURIANZ $444 23 payments
  11. Other $11,693 533 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 60 drugs

Part D claims

3,147

Median for Nurse Practitioner: 389

Drug cost

$1,583,300

Median for Nurse Practitioner: $21,885

Branded share of claims

28.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Soliris Eculizumab Brand 14 $764,666
Ingrezza Valbenazine Tosylate Brand 19 $157,188
Nurtec Odt Rimegepant Sulfate Brand 89 $121,273
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 14 $99,102
Keppra Levetiracetam Brand 45 $82,098
Ubrelvy Ubrogepant Brand 38 $56,074
Fycompa Perampanel Brand 31 $48,639
Aptiom Eslicarbazepine Acetate Brand 14 $34,945
Briviact Brivaracetam Brand 22 $32,947
Nayzilam Midazolam Brand 29 $30,241

The 10 drugs with the highest cost, of 60 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$100,429

Of which drugs: $69,467

Medicare patients

264

Average age 74

Services billed

14,474

162 women, 102 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Chronic kidney disease 33%
Diabetes 32%
Depression 31%
Ischemic heart disease 30%
Alzheimer's or dementia 21%
Atrial fibrillation 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 23 14,000 $69,461

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 43 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Gocovri
  • US WorldMeds, LLC $337
$337 — —
VALTOCO
  • Neurelis, Inc. $333
$333 — —
UBRELVY
  • AbbVie, Inc. $199
$199 38 —
INGREZZA
  • Neurocrine Biosciences, Inc. $189
$189 19 —
VYEPTI
  • Lundbeck LLC $171
$171 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 43 with Patron

Records

724 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record